New therapeutics to treat castrate-resistant prostate cancer

16Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials. © 2013 Ömer Acar et al.

Cite

CITATION STYLE

APA

Acar, Ö., Esen, T., & Lack, N. A. (2013). New therapeutics to treat castrate-resistant prostate cancer. The Scientific World Journal. https://doi.org/10.1155/2013/379641

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free